Neurizon Initiates Dosing in HEALEY ALS Platform Trial

• Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebocontrolled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States • Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and w